Quercetin pretreated umbilical cord mesenchymal stem cells alleviate inflammatory bowel disease via IL-10 /Janus kinase 2/STAT3 signaling

Figure 3 Intraperitoneal injection of quercetin-human umbilical cord-derived mesenchymal stem cells can improve 2,4,6-trinitrobenzenesulfonic acid-induced colitis. A: Experimental flowchart; B: Weight changes, ^aP < 0.05; C: Macroscopic images of the colon; D: Colon length statistical chart, ^aP < 0.05, ^cP < 0.05; E: Survival rate; F: Disease Activity Index (DAI) score to assess the severity of the disease, ^aP < 0.05, 2,4,6-trinitrobenzenesulfonic acid (TNBS) vs TNBS + human umbilical cord-derived mesenchymal stem cells (hUCMSCs), ^cP < 0.05 TNBS vs TNBS + quercetin (QUR)-hUCMSCs; G: On the third day after TNBS induction, the percentage of mouse body weight; H: Colon hematoxylin and eosin staining pathological map. Scale bar = 100 μm; I: Histological Activity Index (HAI) score is used to evaluate the severity of tissue pathology, ^aP < 0.05, ^cP < 0.05; J: Myeloperoxidase (MPO) detection of neutrophil infiltration, ^aP < 0.05, ^cP < 0.05. The data are expressed as the mean ± SEM, n = 6. PBS: Phosphate-buffered saline.